NextPoint Therapeutics
NextPoint Therapeutics is pioneering a new world of precision immuno-oncology and tumor-targeting therapeutics, focusing on the novel B7-H7/HHLA2 pathway. Their mission is to develop first-in-class therapies that can benefit a broad range of cancer patients, including those unresponsive to current treatments like PD-1/L1 inhibitors. Their vision is to revolutionize cancer immunotherapy by targeting unique immune checkpoints and tumor-associated antigens with innovative antibody-based and cell-engaging therapies.
Industries
Nr. of Employees
medium (51-250)
Products
B7-H7-directed checkpoint-blocking antibody (clinical candidate)
A B7-H7/HHLA2-targeting antibody designed to block interaction with the inhibitory receptor while permitting interaction with a stimulatory ligand, with enhanced Fc function to potentiate ADCC; under evaluation in Phase 1 clinical studies.
KIR3DL3-targeting inhibitory receptor antibody (clinical candidate)
An antibody designed to block the inhibitory receptor for the B7-H7 pathway to reverse T and NK cell suppression; under evaluation in Phase 1 clinical studies.
IgG-like T cell engager targeting tumor antigen and CD3 (preclinical/IND planned)
A bispecific, IgG-like T cell engager with two tumor antigen binding domains, a CD3 binding domain, and an inactivated Fc; demonstrates antigen-dependent in vitro cytotoxicity and in vivo efficacy in preclinical models with planned IND submission.
Tumor-targeting antibody-drug conjugate program
Development program for antibody-drug conjugates that use tumor antigen binding to deliver cytotoxic payloads selectively to tumor cells with the target antigen.
B7-H7-directed checkpoint-blocking antibody (clinical candidate)
A B7-H7/HHLA2-targeting antibody designed to block interaction with the inhibitory receptor while permitting interaction with a stimulatory ligand, with enhanced Fc function to potentiate ADCC; under evaluation in Phase 1 clinical studies.
KIR3DL3-targeting inhibitory receptor antibody (clinical candidate)
An antibody designed to block the inhibitory receptor for the B7-H7 pathway to reverse T and NK cell suppression; under evaluation in Phase 1 clinical studies.
IgG-like T cell engager targeting tumor antigen and CD3 (preclinical/IND planned)
A bispecific, IgG-like T cell engager with two tumor antigen binding domains, a CD3 binding domain, and an inactivated Fc; demonstrates antigen-dependent in vitro cytotoxicity and in vivo efficacy in preclinical models with planned IND submission.
Tumor-targeting antibody-drug conjugate program
Development program for antibody-drug conjugates that use tumor antigen binding to deliver cytotoxic payloads selectively to tumor cells with the target antigen.
Services
Partnerships for preclinical evaluation, translational assay development, and biomarker-driven study design to advance therapeutic candidates.
Partnerships for preclinical evaluation, translational assay development, and biomarker-driven study design to advance therapeutic candidates.
Expertise Areas
- Immuno-oncology target discovery
- Monoclonal antibody development
- Antibody-drug conjugate development
- T cell engager (bispecific) development
Key Technologies
- Monoclonal antibody engineering
- Bispecific IgG-like T cell engager platform
- Antibody-drug conjugate linker chemistry
- Fc engineering for enhanced ADCC
News & Updates
Presentation of preclinical data on their novel B7-H7 pathway targeting therapies at AACR 2025.
Presentation of their pipeline targeting B7-H7 in cancer at the Piper Sandler Healthcare Conference 2024.
Participation in the 2024 Stifel Healthcare Conference.
Presentation of their T cell engager therapy targeting B7-H7 at SITC 2024.
Announcement of their new T cell engager NPX372 for solid tumors.
Presentation of preclinical data on their novel B7-H7 pathway targeting therapies at AACR 2025.
Presentation of their pipeline targeting B7-H7 in cancer at the Piper Sandler Healthcare Conference 2024.
Participation in the 2024 Stifel Healthcare Conference.
Presentation of their T cell engager therapy targeting B7-H7 at SITC 2024.
Announcement of their new T cell engager NPX372 for solid tumors.